Companies · Biotechnology
SOUTH SAN FRANCISCO · Biotechnology
Diligence memoA one-page analyst read on Surrozen, Inc./DE — recommendation, valuation, rhythm, risks.→Surrozen, Inc./DE looks fair against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Surrozen, Inc./DE is one of 4291 Biotechnology companies tracked from SOUTH SAN FRANCISCO. By capital raised it ranks among the largest (ahead of 98% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 17%.
Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 98% of sector peers (real $). Modeled value above 85% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #25 of 33.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Kriya Therapeutics, Inc. | Series D+ | $870.3M | $2.5B | 2.79× |
| Pathos AI, Inc. | Series D+ | $365.0M | $2.4B | 2.70× |
| Sensei Biotherapeutics, Inc. | Series D+ | $348.9M | $2.2B | 2.53× |
| Odyssey Therapeutics, Inc. | Series D+ | $590.9M | $1.7B | 1.94× |
| Rhodenergy An Environmental Co Corp | Series D+ | $250.0M | $1.7B | 1.89× |
| Tectonic Therapeutic, Inc. | Series D+ | $333.1M | $1.7B | 1.89× |
| Lumicell, Inc. | Series D+ | $331.1M | $1.7B | 1.89× |
| MapLight Therapeutics, Inc. | Series D+ | $356.2M | $1.5B | 1.65× |
| SAB Biotherapeutics, Inc. | Series D+ | $182.5M | $1.4B | 1.53× |
| Immunic, Inc. | Series D+ | $514.4M | $1.3B | 1.45× |
| Predictive Oncology Inc. | Series D+ | $280.1M | $1.3B | 1.42× |
| Vascular Perfusion Solutions, Inc. | Series D+ | $154.9M | $1.2B | 1.37× |
| Surrozen, Inc./DE this company | Series D+ | $269.4M | $657.8M | 0.74× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series D+ | $193.0M | 2024-04-04 | $1.6B | $2.3B | 90% |
| Series D+ | $76.4M | 2025-03-26 | $636.7M | $657.8M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Craig Parker | — | 4 other | 2024-04 |
| Anna J. Berkenblit, M.D. | — | — | 2024-04 |
| Charles Williams | — | — | 2024-04 |
| Christopher J. Chai | — | — | 2024-04 |
| David J. Woodhouse, Ph.D. | — | — | 2024-04 |
| Eric J. Bjerkholt | — | — | 2024-04 |
| Mace J. Rothenberg, M.D. | — | — | 2024-04 |
| Mary J. Haak-Frendscho, Ph.D. | — | — | 2024-04 |
| Shao-Lee J. Lin, M.D., Ph.D. | — | — | 2024-04 |
| Tim J. Kutzkey, Ph.D. | — | — | 2024-04 |
| Yang J. Li, Ph.D. | — | — | 2025-03 |
Surrozen, Inc./DE is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | Biotechnology | Series D+ | $282.2M | $940.0M | same sector · same stage |
| Dewpoint Therapeutics, Inc. | Biotechnology | Series D+ | $286.2M | $437.6M | same sector · same stage |
| Iambic Therapeutics, Inc. | Biotechnology | Series D+ | $240.9M | $697.2M | same sector · same stage |
| Alumis Inc. | Biotechnology | Series D+ | $240.0M | $432.7M | same sector · same stage |
| Celcuity Inc. | Biotechnology | Series D+ | $303.0M | $691.3M | same sector · same stage |
| Lyra Therapeutics, Inc. | Biotechnology | Series D+ | $236.6M | $790.4M | same sector · same stage |
| Poseida Therapeutics, Inc. | Biotechnology | Series D+ | $231.8M | $369.6M | same sector · same stage |
| Amicus Therapeutics, Inc. | Biotechnology | Series D+ | $314.5M | $420.4M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Surrozen, Inc. | Biotechnology | Series C | $2.0B | 98% |
| SurgiBox Inc. | Biotechnology | Pre-Seed | $750K | 84% |
| RegenX Science Inc. | Biotechnology | Series A | $62.3M | 84% |
| EdenRoc Sciences LLC | Biotechnology | Series C | $21.4M | 84% |
| ReGelTec, Inc. | Biotechnology | Seed | $177.6M | 83% |
| Biorez, Inc. | Biotechnology | Series A | $89.0M | 83% |
| Resolute Science, Inc. | Biotechnology | Seed | $4.7M | 82% |
| Vira Regen Inc. | Biotechnology | Seed | $5.6M | 82% |
See where Surrozen, Inc./DE sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Surrozen, Inc./DE, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.